These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 26014292)

  • 21. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
    J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.
    Seif AE; Walker DM; Li Y; Huang YS; Kavcic M; Torp K; Bagatell R; Fisher BT; Aplenc R
    Pediatr Blood Cancer; 2015 Apr; 62(4):704-9. PubMed ID: 24668949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
    Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
    [No Abstract]   [Full Text] [Related]  

  • 24. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
    Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
    Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Getz KD; Sung L; Alonzo TA; Leger KJ; Gerbing RB; Pollard JA; Cooper T; Kolb EA; Gamis AS; Ky B; Aplenc R
    J Clin Oncol; 2020 Jul; 38(21):2398-2406. PubMed ID: 32343641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group.
    Hastings C; Gaynon PS; Nachman JB; Sather HN; Lu X; Devidas M; Seibel NL
    Br J Haematol; 2015 Feb; 168(4):533-46. PubMed ID: 25308804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database.
    Walker DM; Fisher BT; Seif AE; Huang YS; Torp K; Li Y; Aplenc R
    Pediatr Blood Cancer; 2013 Apr; 60(4):616-20. PubMed ID: 22948886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
    Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
    Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.
    Kelly KM; Sposto R; Hutchinson R; Massey V; McCarten K; Perkins S; Lones M; Villaluna D; Weiner M
    Blood; 2011 Mar; 117(9):2596-603. PubMed ID: 21079154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.
    Kahn JM; Pei Q; Friedman DL; Kaplan J; Keller FG; Hodgson D; Wu Y; Appel BE; Bhatia S; Henderson TO; Schwartz CL; Kelly KM; Castellino SM
    Lancet Haematol; 2022 Jan; 9(1):e49-e57. PubMed ID: 34971582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased mortality after successful treatment for Hodgkin's disease.
    Hudson MM; Poquette CA; Lee J; Greenwald CA; Shah A; Luo X; Thompson EI; Wilimas JA; Kun LE; Crist WM
    J Clin Oncol; 1998 Nov; 16(11):3592-600. PubMed ID: 9817280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.
    Wimmer RS; Chauvenet AR; London WB; Villaluna D; de Alarcon PA; Schwartz CL
    Pediatr Blood Cancer; 2006 Mar; 46(3):320-4. PubMed ID: 16200630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
    Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.
    Parzuchowski A; Bush R; Pei Q; Friedman DL; FitzGerald TJ; Wolden SL; Dharmarajan KV; Constine LS; Laurie F; Kessel SK; Appel B; Fernandez K; Punnett A; Schwartz CL; Cox J; Terezakis SA
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1119-1125. PubMed ID: 29722656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.